Other substances

Novaferon

broad-spectrum antiviral

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

A novel antiviral protein drug which has been approved for the treatment of chronic hepatitis B in China.

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19 Preprint	Patients		alone or in combination with Lopinavir/Ritonavir	Apr/29/2020

AI-suggested references

Link	Publication date
Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19.	Nov/07/2020
Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China	May/06/2020
SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial.	Aug/03/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT05017714	A Trial of Novaferon in Asymptomatic or Mild COVID-19 Patients	Not yet recruiting	Phase 3	Aug/31/2021	Aug/31/2022
Alternative id - Jing302H Interventions - Drug: Recombinant cytokine gene derived protein injection Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 300 Age - 18 Years to 65 Years (Adult, Older Adult) Outcome measures - Time of negative detection of SARS-CoV-2 RNA\|Rate of clinical progression\|the change of viral load\|detection rate of SARS-CoV-2 RNA\|Rate of clinical progression in patients vaccinated\|Rate of clinical progression in subgroup of patients vaccinated\|Rate of clinical progression in patients infected with variants( Delta strain, et al)\|Safety and tolerability
NCT04708158	Novaferon for COVID-19 Treatment Trial (NCTT-005)	Recruiting	Phase 3	Mar/25/2021	Apr/30/2023
Alternative id - JH-COR-005 Interventions - Biological: Novaferon\|Biological: Placebo Study type - Interventional Study results - No Results Available Locations - Chiba Aoba Municipal Hospital, Chiba, Japan\|Kamagaya General Hospital, Chiba, Japan\|NHO Chiba Medical Center, Chiba, Japan\|NHO Omuta National Hospital, Fukuoka, Japan\|NHO Kasumigaura Medical Center, Ibaraki, Japan\|Tsukuba Medical Center Foundation Tsukuba Medical Center Hospital, Ibaraki, Japan\|Kokankai Nippon Kokan Hospital, Kanagawa, Japan\|Rakuwakai Otowa Hospital, Kyoto, Japan\|Okayama City General Medical Center Okayama City Hospital, Okayama, Japan\|Osaka Habikino Medical Center, Osaka, Japan\|Rinku General Medical Center, Osaka, Japan\|Sakai City Medical Center, Osaka, Japan\|Omi Medical Center, Shiga, Japan\|NHO Utsunomiya Hospital, Tochigi, Japan\|Japanese Red Cross Medical Center, Tokyo, Japan\|Juntendo University Hospital, Tokyo, Japan\|Nihon University Itabashi Hospital, Tokyo, Japan\|Showa University East Hospital, Tokyo, Japan\|Showa University Hospital, Tokyo, Japan\|Tokyo Medical University Hachioji Medical Center, Tokyo, Japan\|Tokyo Shinagawa Hospital, Tokyo, Japan\|NHO Iwakuni Clinical Center, Yamaguchi, Japan Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 385 Age - 20 Years and older (Adult, Older Adult) Outcome measures - Time to clinical improvement\|Rate of clinical improvement\|Rate of clinical deterioration\|Time to viral clearance\|Rate of viral clearance\|Change in viral load\|Mortality rate\|Duration of hospital stay\|Time to resolution of symptoms\|Requirement of supplemental oxygen\|Requirement of mechanical ventilation\|Rate of alive patients\|Adverse events
NCT05172037	Novaferon in Non-hospitalized Adult Patients With Mild COVID-19	Recruiting	Phase 3	Oct/28/2021	Jun/01/2022
Alternative id - JH-COR-007 Interventions - Biological: Novaferon\|Biological: Placebo Study type - Interventional Study results - No Results Available Locations - Tokyo Shinagawa Hospital, Tokyo, Japan Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 222 Age - 20 Years and older (Adult, Older Adult) Outcome measures - Rate of severe conditions with Score 3 or more serious on a seven-point ordinal scale from the start date of investigational drug administration (Day 1) to Day 28.
NCT04669015	Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19	Recruiting	Phase 3	Jun/10/2021	Aug/01/2022
Alternative id - JH-COR-003 Interventions - Biological: Novaferon\|Biological: Placebo Study type - Interventional Study results - No Results Available Locations - Hospital Interzonal General de Agudos Dr Jose Penna, Bahia Blanca, Argentina\|CEMIC, Ciudad Autonoma Buenos Aires, Argentina\|Clinica Adventista Belgrano, Ciudad Autonoma Buenos Aires, Argentina\|Clinica Zabala, Ciudad Autonoma de Buenos Aires, Argentina\|Hospital San Roque, Cordoba, Argentina\|Sanatorio del Salvador Privado S.A., Cordoba, Argentina\|Sanatorio Privado Duarte Quiroz De Clinica Colombo SA, Cordoba, Argentina\|Instituto Medico Rio Cuarto, Rio Cuarto, Argentina\|Clinica Central S.A., Villa Regina, Argentina\|HCPA- Hospital de Clínicas de Porto Alegre, Alegre, Brazil\|Fundação PIO XII Hospital de Amor de Barretos, Barretos, Brazil\|Hospital Casa de Saúde Vera Cruz (Coordenador), Campinas, Brazil\|Hospital São José, Criciúma, Brazil\|Hospital das Clínicas UFG, Goiânia, Brazil\|Hospital Geral Prof. Dr. Waldemar de Carvalho Pinto Filho de Guarulhos - BR TRIALS, Guarulhos, Brazil\|Hospital Felício Rocho, Horizonte, Brazil\|Centro de Pesquisas Clínicas da Fundação Doutor Amaral Carvalho, Jaú, Brazil\|CePCLIN - Centro de Estudos e Pesquisas em Moléstias Infecciosas, Natal, Brazil\|Hospital São Luiz de Jabaquara, Porto Alegre, Brazil\|Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil\|Hospital 9 de Julho, São Paulo, Brazil\|Hospital São Luiz de Jabaquara, São Paulo, Brazil\|Instituto de Moléstias Cardiovalsculares Tatuí Ltda, Tatuí, Brazil\|Lóbus Centro de Pesquisa Clínica, Volta Redonda, Brazil\|St Paul's Hospital, Vancouver, Canada\|Hospital Base Osorno, Osorno, Chile\|Hospital Sotero del Rio, Santiago, Chile\|Fundacion Cardiovascular de Colombia - Instituto del Carazon Floridablanco, Floridablanca, Santander, Colombia\|Clínica de la Costa Ltda., Barranquilla, Colombia\|Clinica SOMER, Medellín, Colombia\|Corporacion Clinica, Villavicencio, Colombia\|RS Universitas Udayana, Bali, Indonesia\|M. Djamil Hospital, Padang, Indonesia\|Sardjito Hospital, Yogyakarta, Indonesia\|University Malaya Medical Centre, Kuala Lumpur, Malaysia\|Centro Medico Naval Cirujano Mayor Santiago Tavara, Callao, Peru\|Hospital Nacional Arzobispo Loayza, Lima Cercado, Peru\|Hospital III Daniel Alcides Carrion - Red Essalud de Tacna, Lima, Peru\|Hospital Nacional Dos de Mayo, Lima, Peru\|Tiervlei Trial Centre, Cape Town, South Africa\|Tread Research, Cape Town, South Africa\|Johese Clinical Research: Unitas, Centurion, South Africa\|Drs Sarvan and Moodley, Durban, South Africa\|TASK Eden, George, South Africa\|MERC SiReN, Johannesburg, South Africa\|Nelson Mandela Academic Clinical Research Unit (NeMACRU), Mthatha, South Africa\|Into Research, Pretoria, South Africa\|Dr JM Engelbrecht Trial Site, Somerset West, South Africa\|Clinical Projects Research SA (PTY) LTD, Worcester, South Africa\|Ankara City Hospital, Ankara, Turkey\|Hacettepe University Medical Faculty, Ankara, Turkey\|Dicle University, Medical Faculty, Diyarbakir, Turkey\|Acibadem Atakent Hospital, Istanbul, Turkey\|Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty, Istanbul, Turkey\|Kartal Lutfi Kirdar Research and Training Hospital, Istanbul, Turkey\|Ege University Medical Faculty, Izmir, Turkey\|Kayseri City Hospital, Kayseri, Turkey\|Kocaeli Universitesi Tip Fakultesi, Kocaeli, Turkey\|Selcuk Universitesi Selcuklu Tip Fakultesi Hastanesi, Konya, Turkey\|Ondokuz Mayis Univ. Med. Fac., Samsun, Turkey\|Karadeniz Tecnical Uni. Med. Fac., Trabzon, Turkey\|CI Dnipropetrovsk CCH #6 of DRC Dept of Therapy (with pulmonological beds) SI DMA of MoHU, Dnipro, Ukraine\|CNE CCH #16 of Dnipro City Council, DSMU, Ch of Intern Med #1, Dnipro, Ukraine\|CNE Ivano-Frankivsk Reg Clin Infectious Hospital of Ivano-Frankivsk Regional Council, Ivano-Frankivsk, Ukraine\|CNE of Kharkov RC Reg Cl Infectious Hospital, Kharkiv, Ukraine\|Communal Non-Commercial Medical Enterprise "O.T.Bohayevskyi Kremenchuk City Hospital #1", Kremenchuk, Ukraine\|Kyiv Municipal Clinical Hospital #17 O. O. Bogomolets NMU, Kyiv, Ukraine\|City Hospital #1, Mykolaiv, Ukraine\|City Clinical infectious Hospital, Odesa, Ukraine\|Poltava Regional Clinical Infectious Hospital Dept of Diagnostics HSEIU Ukrainian Medical Stomatolog, Poltava, Ukraine\|Municipal Non-Profit Enterprise Central City Hospital Of Rivne City Council, Rivne, Ukraine\|CCH #1 Vinnytsia M.I.Pyrogov NMU Ch of Infectious Diseases, Vinnytsia, Ukraine\|CI Central City Hospital #1 of Zhytomyr, Zhytomyr, Ukraine Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 914 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Rate of clinical deterioration\|Rate of recovery\|Hospital discharge rate\|Mortality rate\|Duration of hospitalization\|Adverse events